Gliederung

Background

Treatment of patients with trauma keratitis represents a significant problem encountered in the eye clinic, and yet the management of this condition has not been effective so far. The abstract presents data on clinical trial of a new liposome eye medication Lipophlavon, containing antioxidant, kvertsetin, phosphatidilholine lecitin, its effectiveness for the complex treatment of trauma keratitis.

Aims

To investigate the effectiveness of Lipophlavon for the complex treatment of the patients with trauma keratitis.

Methods

The study included 120 patients (120 eyes) with trauma keratitis. The patients were randomly split into two groups similar in age and sex. The patients of the study group (80 people, 80 eyes) were given Lipophlavon instillations, eye drops manufactured by “Biolek” (Kharkov, Ukraine), up to 6-8 times a day as a component of a standard treatment. The patients of the control group underwent standard treatment only (cyloxan instillations 4 times a day, solcoseril-gel). Traditional clinical ophthalmic research methods were used.

Results

Lipophlavon is well tolerated, it doesn’t produce side effects or allergic reactions. Lipophlavon is effective in the treatment of the patients with trauma keratitis: fluorescin test shows a 2,1 times speedier epitalization, the period of full recovery is 2,0Â±0,06 days shorter, eye pain and subjective complaints persist 2,7Â±0,03 days shorter as compared to the control group.

Summary/Conclusions

The results of the clinical trial have made it possible to recommend Lipophlavon as an eye medication speeding up regeneration and full recovery as well as an effective anti-inflammatory drug in the complex treatment of trauma keratitis.